---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Conclusions"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Conclusions. 1 evidence topic quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary/conclusions"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Conclusions

<a id="heading-1.1.4"></a>

## 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

### Summary

CIDP affected an estimated 77,058 individuals in the United States in 2023, 78% of patients in one survey had a progressive or relapsing course, and in US claims mean total costs were 7.5 times those of matched controls ($116,330 compared with $15,586), with CIDP therapy accounting for 51.2% of mean total costs among cases. Around a third of patients do not respond to current treatments and approximately two-thirds need long-term intravenous immunoglobulin. For Vyvgart Hytrulo (efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase), approved for CIDP in June 2024, CDA-AMC estimated $1,872,111 per QALY gained for efgartigimod alfa injection compared with immunoglobulin, and NICE draft guidance states that efgartigimod should not be used.

Claseprubart is an investigational monoclonal antibody that selectively inhibits the active form of C1s. The evidence in CIDP consists of an open-label interim analysis of 40 participants in Part A of the phase 3 CAPTIVATE trial, in which 75% were confirmed responders and no treatment-related serious adverse events or serious infections were reported, together with phase 1 data in healthy volunteers. No randomized results, peer-reviewed publication, price, or budget impact model exist. The company believes that CAPTIVATE, as a single pivotal trial, will support a Biologics License Application, with Part B top-line results expected by the end of 2028. The company states that the safety and efficacy of claseprubart have not been evaluated in head-to-head comparative clinical studies.

Source: [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/); [Aotsuka et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38408295/); [Divino et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6198979/); [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf); [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm); [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1); [Allen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39304241/); [van Schaik et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29122523/); [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm); [CDA-AMC efgartigimod alfa reimbursement recommendation (2026)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/SR0894/2990?inline=1); [NICE ID6409 draft guidance (2026)](https://www.nice.org.uk/guidance/gid-ta11508/documents/draft-guidance-2); [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9); [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm); [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
